Exelixis (EXEL) Demonstrates Advanced Prostate Cancer Advances

Exelixis, Inc. (NASDAQ:EXEL) today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. These data confirm cabozantinib’s effects on metastatic bone lesions and soft tissue disease, and demonstrate a positive impact on bone related pain and narcotic use, as well as biomarkers of bone formation and resorption. Matthew R. Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center and an investigator on the trial, presented the data today in an oral session at the American Society of Clinical Oncology 2012 Annual Meeting (Abstract #4513), which is taking place in Chicago, Illinois. In addition, preliminary results from an ongoing phase 1 investigator-sponsored trial (IST) designed to determine the lowest effective dose of cabozantinib for the treatment of men with CRPC and bone metastases were also presented at the conference. Richard J. Lee, M.D., Ph.D., Assistant Physician in the Department of Medicine at Massachusetts General Hospital Cancer Center, and an investigator on the study, presented the data yesterday in a poster discussion session (Abstract #4566).

Both presentations are available at http://www.exelixis.com/resources/events/asco-2012.

Cabozantinib in Chemotherapy-Pretreated Metastatic CRPC: Interim Results from a Phase 2 Non-Randomized Expansion Cohort

The interim results reported today include data from 93 men enrolled in the ongoing non-randomized expansion (NRE) 100 mg cohort of the company’s phase 2 randomized discontinuation trial. All patients had bone metastases on bone scan and 46% had measurable soft tissue disease. All patients had received prior docetaxel, 35% had prior abiraterone or MDV3100, and 24% had received prior cabazitaxel. Bone directed therapies such as zoledronic acid, denosumab and alpharadin were used in 57%, 14% and 1% of patients, respectively. Seventy-three percent of patients had received at least 2 prior lines of therapy for CRPC. Clinically significant pain, defined as baseline pain score by Brief Pain Inventory (BPI) ≥4, was present in 44% of patients, with the majority requiring chronic narcotic administration.

Bone Scan Response (BSR). Computer-assisted evaluation of bone scan lesion area (BSLA) was determined by an Independent Radiology Committee (IRC) and showed an overall BSR rate (complete response + partial response) of 67%. Another 16% of patients had stable disease and 8% had a best response of progressive disease. Median best BSLA change was a reduction of 60%, and reductions were observed in patients with prior abiraterone, MDV3100, cabazitaxel, and/or radionuclide therapy. The median duration of bone scan response was 5.4 months (range 5.0 – 6.9 months).

Pain Palliation. In 39 patients with clinically significant baseline pain, the median maximal reduction in pain from baseline was 46%. A clinically significant reduction of pain, defined as a ≥30% decrease in pain score, was observed in 25 patients (64%). Fifty-six percent of patients decreased their use of narcotics, including 31% who discontinued narcotics. These improvements were observed in patients with a variety of prior therapies.

Circulating Tumor Cells. Robust reductions in circulating tumor cells (CTCs) were observed regardless of prior therapy in 62 patients with baseline CTC counts ≥5/7.5 mL of blood and a week 6 and/or week 12 assessment. Fifty-seven patients (92%) had ≥30% decrease in their CTC count. Thirty-nine percent of evaluable patients converted to <5 CTCs at week 6.

Progression-Free Survival (PFS). Analyses of progression free survival based on radiographic progression per IRC in soft tissue and/or bone included either the total population (N=93) or only patients who had received prior docetaxel and abiraterone (n= 29). Median progression-free survival was 4.2 months (95% CI 4.1, 6.6) for the total population, and 4.6 months (95% CI 2.9, 8.3) for patients who had previously received docetaxel and abiraterone.

Bone Biomarkers. Substantial decreases were seen in serum levels of cross-linked C-terminal telopeptides of type 1 collagen (CTx) and bone-specific alkaline phosphatase (BSAP), which are biomarkers of bone metabolism. Reductions occurred in patients previously treated with bone directed therapy such as zoledronic acid or denosumab.

Safety Results. The most frequently reported adverse events (AEs) of grade 3 or higher, regardless of causality, were: fatigue (28%), diarrhea (11%), nausea (10%), hypertension (9%), back pain (7%), decreased appetite (6%), venous thrombosis (6%), hand-foot syndrome (5%), dyspnea (5%), vomiting (4%), and decreased weight (3%). A single related grade 5 event was observed in a patient with extensive liver metastases and abnormal liver function tests at baseline who went on to experience portal vein thrombosis and subsequent liver failure.

“The effects of cabozantinib on bone metastases, soft-tissue metastases, and pain are compelling. In men with bone-predominant disease, the most common phenotype in metastatic CRPC, the impact was particularly profound,” said Dr. Smith. “The scope of activity of cabozantinib as a single agent is unique relative to approved agents or agents in development. The compound’s ability to positively impact PFS, bone scan response, circulating tumor cells, pain, and bone turnover markers demonstrates its potential as an important new agent in CRPC.”

Trial Results of Low-Dose Cabozantinib in Treating Bone Metastases in CRPC

This dose-ranging study used an adaptive design. Dose levels of 20 and 40 mg daily cabozantinib were explored, with BSR as the primary endpoint. Additionally, CTCs and safety were assessed.

In Cohort 1 (40 mg daily cabozantinib), 10 of 11 evaluable patients (91%) had a BSR at week 6, comprising 1 complete response (CR) and 9 partial responses (PRs). A lower BSR rate (10%) was observed in Cohort 2, with 10 evaluable patients receiving 20 mg. Therefore, an expansion cohort of 13 patients was enrolled at 40 mg. The week 6 BSR rate among all 24 patients who received a 40 mg daily dose of cabozantinib was 67%.

Patients receiving 40 mg of cabozantinib were included in the CTC assessment. Twelve of 21 evaluable patients had baseline CTCs ≥5/7.5 mL of blood. Eleven of these 12 patients (92%) demonstrated best CTC decrease ≥30%, and 7 patients (58%) converted to <5 CTCs.

None of the patients receiving cabozantinib at either 20 or 40 mg daily required dose reductions or interruptions during the first 12 weeks of treatment. A patient in Cohort 1 discontinued treatment at week 2 for worsening of preexisting fatigue, weight loss, and anorexia. In Cohort 2 and the expansion cohort, a total of three patients discontinued treatment due to a venous thromboembolic event.

“These new data reinforce cabozantinib’s differentiated clinical profile and potential utility for the treatment of men with metastatic CRPC,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “The durable improvements in bone scans and bone pain, the high rate of tumor regression, and other indicators of clinical activity observed in these trials support using overall survival and bone pain response as the endpoints for our two recently initiated prostate cancer phase 3 pivotal trials, COMET-1 and COMET-2, respectively. We believe these two pivotal trials provide us the best opportunity to maximize the clinical and commercial potential of cabozantinib in CRPC.”

The Significance of Bone Metastases in CRPC

The primary cause of morbidity and mortality in patients with CRPC is metastasis to the bone, which occurs in about 90% of cases. Bone metastases cause local disruption of normal bone remodeling, with lesions generally showing a propensity for an osteoblastic (bone-forming) phenotype on imaging. These lesions often lead to increased skeletal fractures, spinal cord compression, and severe bone pain. Osteoblastic lesions are typically visualized in CRPC patients by bone scan, which detects rapid incorporation of 99mTc-labeled methylene-diphosphonate radiotracer into newly forming bone. In addition, increased blood levels of BSAP and CTx, markers for osteoblast and osteoclast activity, respectively, are often observed in CRPC patients with bone metastases, and are associated with shorter overall survival.

About Cabozantinib

Cabozantinib is a potent targeted therapy that inhibits MET and VEGFR2. Cabozantinib is an investigational agent that provides coordinated inhibition of metastasis and angiogenesis to kill tumor cells while blocking their escape pathways. The therapeutic role of cabozantinib is currently being investigated across several tumor types. MET is upregulated in many tumor types, thus facilitating tumor cell escape by promoting the formation of more aggressive phenotypes, resulting in metastasis. MET-driven metastasis may be further stimulated by hypoxic conditions in the tumor environment, which are often exacerbated by selective VEGF-pathway inhibitors. In preclinical studies, cabozantinib has shown powerful tumoricidal, antimetastatic and antiangiogenic effects, including:

• Extensive apoptosis of malignant cells
• Decreased tumor invasiveness and metastasis
• Decreased tumor and endothelial cell proliferation
• Blockade of metastatic bone lesion progression
• Disruption of tumor vasculature

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company’s web site at www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: the continued development and clinical, therapeutic and commercial potential of, and opportunities for, cabozantinib; the potential of cabozantinib as an important new agent in CRPC; the belief that the referenced data support using overall survival and bone pain response as the endpoints for Exelixis’ two recently initiated prostate cancer phase 3 pivotal trials, COMET-1 and COMET-2; and the belief that the COMET-1 and COMET-2 trials provide Exelixis with the best opportunity to maximize the clinical and commercial potential of cabozantinib in CRPC. Words such as “demonstrates,” “potential,” “support,” “opportunity,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Exelixis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to the potential failure of cabozantinib to demonstrate safety and efficacy in clinical testing; Exelixis’ ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion; the sufficiency of Exelixis’ capital and other resources; the uncertain timing and level of expenses associated with the development of cabozantinib; the uncertainty of the FDA approval process; timely receipt of potential reimbursements, milestones, royalties and profits under Exelixis’ collaborative agreements; Exelixis’ ability to enter into new collaborations; market competition; and changes in economic and business conditions. These and other risk factors are discussed under “Risk Factors” and elsewhere in Exelixis’ quarterly report on Form 10-Q for the quarter ended March 30, 2012 and Exelixis’ other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Complete Genomics (GNOM) Announces Restructuring Plan and Review of Strategic Alternatives

Company to Focus on Clinical Sequencing While Continuing to Deliver High-Quality Genomes to Researchers

MOUNTAIN VIEW, Calif., June 5, 2012 (GLOBE NEWSWIRE) — Complete Genomics, Inc. (Nasdaq:GNOM), today announced that it is taking steps to reduce cash consumption and has engaged Jefferies & Company, Inc. to assist it in exploring strategic alternatives. The company also plans to focus on development of clinical applications for its whole human genome sequencing service, while continuing to provide high-quality genomes to research customers.

“Leading hospitals, health care systems and physicians are beginning to adopt whole human genome sequencing for clinical applications,” said Dr. Clifford Reid, Complete’s Chairman, President, and CEO. “Our industry-leading accuracy should position us well to capture this emerging opportunity.”

Complete will maintain its current monthly capacity of approximately 1,000 genomes at 40x coverage or 500 genomes at 80x coverage. The company expects to delay capacity expansion beyond those numbers until demand for clinical-grade genomes supports expansion. The delay in expanding capacity is resulting in deferred capital expenditures and job cuts, primarily in field and factory headcount. Approximately 55 employee positions in Mountain View, California, and other U.S. locations will be eliminated.

This employee reduction is expected to be substantially completed during the current quarter ending June 30, 2012. Restructuring and related costs incurred with this plan are estimated at $1.5 million, most of which will be cash expenditures. These costs are comprised of one-time termination benefits for employees whose positions are being eliminated and should be recorded this quarter.

Complete Engages Jefferies & Company As Financial Advisor

Complete also announced that it has engaged Jefferies & Company, Inc. to act as financial advisor to the company and to assist in its review of strategic alternatives, which could include a merger, business combination, equity investment, or sale.

No decision has been made to enter into a transaction at this time, and there can be no assurance Complete will enter into a transaction in the future.   The company does not plan to disclose or comment on developments regarding the strategic review process until it is complete or further disclosure is deemed appropriate.

About Complete Genomics

Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines proprietary human genome sequencing technology with advanced informatics and data management software. Additional information can be found at www.completegenomics.com.

Caution Regarding Forward-Looking Statements

This Press Release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the ability of Complete to capture a portion of the market opportunity for whole human genome sequencing for clinical applications, the amount and timing of the company’s restructuring-related costs and cash expenditures, and future capacity. These forward-looking statements are based on management’s current expectations, are not guarantees of future performance, and involve certain risks and uncertainties that could cause actual results to differ materially from management’s current expectations and these forward looking statements. These risk and uncertainties include, but are not limited to, the rate of adoption of whole human genome sequencing for clinical applications, competition, Complete’s ability to execute on the restructuring plan within the time frame and at the costs estimated above, and other risks detailed in Complete’s most recent Annual Report on Form 10-K, filed with the SEC on March 9, 2012, and Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2012. We disclaim any obligation to update information contained in our forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Complete Genomics, Inc.
         Scott Sandler
         Investor Relations
         (650) 943-2788
         ssandler@completegenomics.com

GCI And Alaska Communications (ALSK) Form The Alaska Wireless Network

– Wireless Facilities Company Formed To Operate Alaska’s Largest Network, Covering More than 95 percent of the State’s Population – Network Will Provide Next Generation Wireless Services To Alaska Communications and GCI Subscribers – The Alaska Wireless Network Is A Competitive Response To National Carriers

JA Solar (JASO) Announces First Quarter 2012 Results

SHANGHAI, China, June 5, 2012 (GLOBE NEWSWIRE) — JA Solar Holdings Co., Ltd., (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced its unaudited financial results for its first quarter ended March 31, 2012.

First Quarter 2012 Highlights

• Shipments were 366 MW, above the high end of the Company’s previous guidance of 350 MW and a decrease of 8.1% from the fourth quarter of 2011
• Net revenue was RMB 1.6 billion ($254.4 million), compared to RMB 1.95 billion ($309.0 million) in the fourth quarter of 2011
• Gross margin, including provisions for potential countervailing and anti-dumping duties totaling $2.9 million, was 2.1%, compared to gross margin of 0.5% in the fourth quarter of 2011
• Operating loss was RMB 159.1 million ($25.3 million), compared to operating loss of RMB 487.6 million ($77.4 million) in the fourth quarter of 2011
• Net loss was RMB 250.9 million ($39.8 million) and loss per diluted ADS was RMB 1.28 ($0.20), compared to loss per diluted ADS of RMB 2.45 ($0.39) in the fourth quarter of 2011
• Operating cash flow was RMB 114.8 million ($18.2 million), compared to RMB 545.3 million ($86.6 million) in the fourth quarter of 2011
• Cash and cash equivalents at the end of the quarter were RMB 4.3 billion ($676.2 million), compared to RMB 3.9 billion ($617.6 million) at the end of the fourth quarter of 2011

Dr. Peng Fang, CEO of JA Solar, commented, “Despite the seasonal impact of the Chinese New Year holiday, we achieved shipments of 366 MW in the first quarter, above the high end of our previous guidance. Our results for the first quarter demonstrate the effectiveness of our strategy to ensure JA Solar’s long-term sustainability through the current volatile market environment. Through prudent balance sheet management, we recorded positive operating cash flow of RMB 114.8 million. With industry-wide overcapacity continuing, we nevertheless recorded positive gross margin and positive EBITDA. This enabled us to maintain a relatively healthy balance sheet – one of the strongest in the industry – which gives customers and financial institutions confidence in JA Solar as a long-term partner. Across the industry, we have seen a shift where customers are seeking quality suppliers who can demonstrate both financial and technological strength. Going forward, we expect that JA Solar will increasingly benefit from this trend, as we build our presence in key markets and grow demand for our high-efficiency products.

“Demand for our cells and modules remains strong. In Germany and Italy, sales in the first quarter were above our expectations. In both markets we see a trend towards rooftop installations, to which JA Solar’s high-efficiency product offerings are ideally suited. In the first quarter we also focused on expansion into promising new markets such as Japan, India and the Middle East. We expect that Japan, for example, will be an important market for JA Solar. Few suppliers can meet Japanese customers’ rigorous standards for product quality and reliability, and our continued growth in this market is a testament to the superiority of our offering. We now have a local sales team on the ground, which is working to build out our fruitful relationships with Japanese customers, and we expect to record meaningful shipments to Japan in the coming quarters. In China, we have carefully nurtured strong partnerships with some of the leading project developers and EPCs and we expect shipments to Chinese customers to increase substantially in 2012.

“While we are disappointed by the U.S. Department of Commerce’s preliminary decision on anti-dumping duties last month, since last year we have worked to ensure that JA Solar is relatively insulated from the impact of this ruling. The majority of our products sold in the U.S. market in the first quarter contained cells produced by our partners outside of mainland China. Therefore, our exposure to potential government tariffs is relatively small and we believe that JA Solar is significantly less exposed than our peers. We estimate that less than 10 MW of the products we shipped to the U.S. in Q1 will be subject to tariffs if the provisional ruling is ratified, and we have recorded a related provision of approximately $2.9 million in the first quarter.

“Globally, we have seen that both potential and existing customers are increasingly relying on strong and dependable Tier One suppliers. I’m therefore confident that JA Solar’s strong balance sheet, prudent cash management strategy, and high-quality product offerings that are well suited to changing industry demands, position us for long-term success.”

First Quarter 2012 Financial Results

Total shipments in the first quarter of 2012 were 366 MW, above the high end of the Company’s previously provided guidance of 320 MW to 350 MW. This represents an 8.1% decline from 398 MW in the fourth quarter of 2011 and an 18.9% decrease from 451 MW in the first quarter of 2011.

Revenue in the first quarter of 2012 was RMB 1.6 billion ($254.4 million), a decrease of 17.7% from RMB 1.95 billion ($309.0 million) reported in the fourth quarter of 2011 and a decrease of 56.0% from RMB 3.6 billion ($578.5 million) reported in the first quarter of 2011.

Gross profit in the first quarter of 2012 was RMB 33.2 million ($5.3 million), compared with a gross profit of RMB 9.1 million ($1.4 million) in the fourth quarter of 2011 and gross profit of RMB 630.3 million ($100.1 million) in the first quarter of 2011. Gross margin, including provisions for potential countervailing and anti-dumping duties, was 2.1% in the first quarter of 2012, compared with 0.5% in the fourth quarter of 2011 and 17.3% in the first quarter of 2011. Excluding the provisions for potential countervailing and anti-dumping duties, gross margin would have been 3.2% in the first quarter of 2012.

Total operating expenses in the first quarter of 2012, were RMB 192.4 million ($30.5 million), compared with RMB 496.7 million ($78.9 million) in the fourth quarter of 2011 and RMB 85.0 million ($13.5 million) in the first quarter of 2011. The decrease in total operating expenses quarter over quarter was primarily due to a long-lived asset impairment loss of RMB 303.1 million ($48.1 million) recorded in the fourth quarter of 2011.

Operating loss in the first quarter of 2012 was RMB 159.1 million ($25.3 million), compared with an operating loss of RMB 487.6 million ($77.4 million) in the fourth quarter of 2011 and operating income of RMB 545.4 million ($86.6 million) in the first quarter of 2011. Operating margin was negative 9.9% in the first quarter of 2012, compared with negative 25.1% in the fourth quarter of 2011 and a positive operating margin of 15.0% in the first quarter of 2011.

Other income in the first quarter of 2012 was RMB 32.1 million ($5.1 million), compared with other income of RMB 208.9 million ($33.2 million) in the fourth quarter of 2011 and other income of RMB 54.4 million ($8.6 million) in the first quarter of 2011.

Loss per diluted ADS in the first quarter of 2012 was RMB 1.28 ($0.20), compared with loss per diluted ADS of RMB 2.45 ($0.39) in the fourth quarter of 2011 and earnings per diluted ADS of RMB 2.68 ($0.43) in the first quarter of 2011.

In the first quarter of 2012, the Company generated operating cash flow of RMB 114.8 million ($18.2 million).

Liquidity

The Company maintained a strong balance sheet with cash and cash equivalents of RMB 4.3 billion ($676.2 million), and total working capital of RMB 3.7 billion ($591.9 million) at March 31, 2012. Total short-term bank borrowings were RMB 968.3 million ($153.8 million). Total long-term bank borrowings were RMB 4.4 billion ($697.9 million), among which RMB 1.4 billion ($226.0 million) were due in one year. The total face value of outstanding convertible bonds due 2013 was RMB 1.4 billion ($220.7 million) at March 31, 2012.

Business Outlook

For the second quarter of 2012, the Company expects total cell and module shipments to be between 420 MW and 440 MW. The Company’s full year guidance of 1.8 GW to 2 GW remains unchanged.

Investor Conference Call / Webcast Details

A conference call has been scheduled for today, Tuesday, June 5, 2012, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong Time). The call may be accessed by dialing +65-6723-9381 (international), +1-718-354-1231 (U.S.), or +852-2475-0994 (Hong Kong). The passcode is JA Solar. A live webcast of the conference call will be available on the Company’s website at www.jasolar.com. A replay of the call will be available beginning two hours after the live call and will be accessible by dialing +61-2-8235-5000 (international) or +1-718-354-1232 (U.S.). The passcode for the replay is 83573982.

Currency Convenience Translation

The conversion of Renminbi into U.S. dollars in this release, made solely for the convenience of the reader, is based on the noon buying rate in the city of New York for cable transfers of Renminbi as certified for customs purposes by the Federal Reserve Bank of New York as of March 30, 2012, which was RMB 6.2975 to $1.00. No representation is intended to imply that the Renminbi amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on March 30, 2012, or at any other date. The percentages stated in this press release are calculated based on Renminbi.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words such as “may,” “expect,” “anticipate,” “aim,” “intend,” “plan,” “believe,” “estimate,” “potential,” “continue,” and other similar statements. Statements other than statements of historical facts in this announcement are forward-looking statements, including but not limited to, our expectations regarding the expansion of our manufacturing capacities, our future business development, and our beliefs regarding our production output and production outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Further information regarding these and other risks is included in Form 20-F and other documents filed with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

About JA Solar Holdings Co., Ltd.

JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation. The Company is one of the world’s largest producers of solar cells. Its standard and high-efficiency product offerings are among the most powerful and cost-effective in the industry. The Company also produces solar modules which it distributes under its own brand and produces on behalf of solar manufacturers globally. The Company shipped 1.69GW of solar power products in 2011. JA Solar is headquartered in Shanghai, China, and maintains production facilities in Shanghai, as well as Hebei, Jiangsu and Anhui provinces.

For more information, please visit www.jasolar.com.

The JA Solar Holdings Co., Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8631

CONTACT: In China

         Martin Reidy
         Brunswick Group
         Tel: +86-10-5960-8600
         E-mail:jasolar@brunswickgroup.com

         In the U.S.

         Cindy Zheng
         Brunswick Group
         Tel: +1-212-333-3810
         E-mail:jasolar@brunswickgroup.com

SEFE (SEFE) CEO Issues Letter to Shareholders

SEFE, Inc. (OTCBB/OTCQB: SEFE), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today provides the following letter to its stockholders and the investment community from its CEO, Don Johnston.

To our valued Shareholders:

I’d like to update you on the status of the company’s technological developments and operational changes. We’ve made much progress in the last four years, taking a seemingly impossible concept and developing it into a solution with many applications in different industries. We call our system the Harmony III.

Briefly, the Harmony III utilizes the phenomena of atmospheric corona discharge by a proprietary collection element held in the air by a balloon. The earth’s natural electrical field drives the discharge, and ions in the lower atmosphere provide a sink for the current. The solution is a high voltage and relatively low current technique by nature and requires a careful approach to handling the power.

Our engineering team has been extremely busy, and we’ve filed for patents on many of the aspects of this unique energy gathering system. The last 90 days have been very productive, and we’d like to share the results with you.

We’ve filed for a patent on our strain reduction system that uses an elastic bungee between a balloon and the tether attached to the balloon. As wind pushes on the balloon, the immediate pressure is absorbed by the elastic bungee rather than the balloon or the tether. This reduces the immediate force and tension, protecting critical components from damage.

Additionally, we’ve filed for patent protection on our tether contact system. The tether contact system is designed to minimize the electrical path length on the power tether. The system uses a proprietary mechanism to complete the power circuit, removing the unused power tether from the path. This system functions in tandem with the dynamic electrical converter and the electrostatic motor-generator as an efficiency booster. This allows for the same hardware to be used no matter what the flight elevation of the aerostat (the technical name for the balloon) may be.

We’ve also filed for patent protection on our system for detecting the concentration of atmospheric ions in the lower atmosphere at varying elevations. The charge detection system will play a critical role in broadening SEFE’s client base, allowing us to quickly determine how to best deliver the required amount of power to the client.

As our research and methodologies have progressed, we’ve realized we need a better balloon launch and retrieval system. So our engineers came up with the “Balloon Launch Assist” system, which uses a secondary stabilizing balloon on top of the primary lift balloon. This invention allows the balloon to be launched and retrieved in a simple manner, without a need for the extra manpower usually associated with the initial launch of a balloon. The secondary balloon provides upward lift and prevents the primary balloon from tipping over, ensuring stability during the critical stages of initial balloon deployment as well as during retrieval. The invention is currently in the patent application process with the U.S. Patent and Trademark Office. A patent-pending number has not yet been issued.

We’re also in the process of designing an electrostatic motor that operates as a generator when supplied with a high voltage-low current power source. This motor will be a key piece of the electrical generation hardware for our Harmony III system. It is designed to work side-by-side with our electrical converter to produce usable AC power directly for immediate consumption, delivery to an electrical grid, or stored for later use.

Our engineers have modified the original ion detector design for a more flight suited geometry which we are calling our “Cubic Wire Detector.” The IP for this technology has been categorized as a “continuation-in-part” application, adding a variation to SEFE’s patent-pending application for Collection of Atmospheric Ions while claiming priority based on the original patent, which was filed with the U.S. Patent and Trademark Office on May 12, 2011. The variation employs an open-frame cubic box with alternating wires rather than parallel plates to collect atmospheric ions. The Cubic Wire Detector provides valuable insight into where the most abundant source of atmospheric charge is located.

We believe the cubic wire geometry is more suited to the flight environment and in its second iteration will also be able to capture directionality, depletion, and charge mobility measurements. The alternating wires are held at a high voltage and the ions that pass between the wires are accelerated by the high voltage and measured as a current. The team has developed a custom software routine to automate the data collection and allow for the test operator to adjust test parameters in flight. The software has gone through several iterations over the past year and is currently performing as expected in laboratory tests utilizing an ion source.

As you can see, our engineers are very busy developing Harmony III so it can become a huge success. Our operational staff has adeptly kept pace with several important developments, as well.

While we continue our efforts to advance the capabilities of the Harmony III system, we are working the marketing side at the same time. We’ve launched Revmodo to keep investors and the public up to date on developments in clean energy and the clean energy business. Revmodo has created an online presence that is geared toward driving potential new business to SEFE through community outreach initiatives and education of the public about the growing clean technology space.

Shea Gunther and Michael d’Estries, two award-winning green marketing veterans whose experience ranges from Glamour to Forbes, and from the Huffington Post to the Mother Nature Network and GE’s ecomagination.com, built the site for us and we are very pleased with their efforts. We feel that Revmodo will provide us with unique opportunities to foster new clean energy concepts, and believe it will also enable access to a wide variety of potential business partners that will bolster our company’s commercial opportunities. If you have not yet viewed the Revmodo site, I encourage you to do so.

Earlier this year, we moved our headquarters to Boulder, Colorado. We believe our Boulder facility provides us with an optimal setting for continued testing and perfection of our Harmony III system. We’re also pursuing a partnership with the University of Colorado’s Department of Electrical and Computer Engineering. We plan to work with both the Colorado Center for Power Electronics and the Center for Environmental Technology to perform research and development related to the physics and engineering of the Harmony III system. We believe the University will be a valuable partner in our efforts to further advance the development of our atmospheric energy technology.

Finally, we have set the following milestones on the path toward commercializing the Harmony III:

• Completing the data collection to determine how much electricity can be generated and stored by each unit over a period of time based on location, altitude, weather, and other factors;
• Securing contracts with mining organizations and/or utility companies;
• Implementation of the communications, monitoring methodologies, and security for each unit through our Network Operations Center (NOC) where applicable.

Please feel free to contact us with any questions you may have. We very much appreciate the continued support of our investors and are committed to delivering long-term shareholder value to all of you.

Sincerely,

Donald C. Johnston, CEO
SEFE, Inc.
4700 Sterling Drive
Boulder, CO 80301
T: (303) 444-0584
F: (303) 444-0571

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

India Globalization Capital (IGC) Announces the Creation of a China Advisory Board

BETHESDA, MD — (Marketwire) — 06/04/12 — India Globalization Capital, Inc. (NYSE MKT: IGC) (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in India and China, announced today the creation of an advisory board for China. The members will advise the Company’s directors and management on business transactions, mergers and acquisitions, corporate governance, including internal controls in China and in general act as a panel of experts. The initial members have extensive experience in Inner Mongolia Autonomous Region, China, where the Company has articulated a strategy of acquiring mines. Inner Mongolia is a vast area in China that has some of the largest deposits of Iron Ore, Copper, Coal, Gold and 90% of the Chinese rare earth minerals.

Ram Mukunda, CEO of IGC, said: “We are pleased to announce the appointment of four individuals with extensive experience in the mining sector in Inner Mongolia. Apart from their diverse experience, the three Senior Advisors have extensive business contacts and all three have reputations of high integrity. They are also major shareholders of IGC.”

Mukunda added, “Now that our Chinese shareholders have no IGC Board seats, the Advisory Board will streamline our governance in China. As we reported earlier, contractually IGC has Board control of the Hong Kong holding company and the PRC operating company. The Advisory Board gives our largest Chinese shareholders and their key advisors a voice in ongoing operations and greater access to our board. Our management team expects to draw on their experience in rapidly expanding the platform we now have in Inner Mongolia and to bolster our presence and production capability. Once the current platform is adequately integrated with the appropriate people, processes and reporting, we will enter into a dialogue with other acquisition candidates.”

The China Advisory Board comprises of the following individuals:

Senior Advisor: Mr. Hua Zhang is an entrepreneur and business leader in the Chifeng region of Inner Mongolia. He graduated from the Chinese Central Party School where he studied economics and management. He is currently the Chairman and CEO of several companies including a leading real estate development company, chrysanthemum extract development as well as Iron ore mining. In 2001 he was recognized as the Outstanding Young Entrepreneur. Since 2003 he has served as the Vice Director of the Chifeng City Chamber of Commerce. In 2004 he was recognized as the Outstanding Builder of Inner Mongolia. He is very active in Project Hope that helps individuals in Inner Mongolia obtain an education and work skills. Mr. Zhang was the former Chairman and Legal Representative of Ironman and is a major stockholder of IGC.

Senior Advisor: Mr. BenQuan Li has over 30 years of mining experience and is a highly respected entrepreneur in the mining industry of Chifeng. He has operated, owned and invested in Lead, Zinc, and Iron ore mines in Inner Mongolia. He possesses a unique knowledge of the geology of the region having lived and worked in the mining sector for most of his career. He is currently the Chairman of Weng Niu Te County Huayin Mining and a member of the Chinese People’s Political Consultative Conference (CPPCC) of Weng Niu Te County. Mr. BenQuan Li is a major stock holder of IGC.

Senior Advisor: Mr. JingYu Mu has over 30 years of mining experience, and is a highly respected entrepreneur in the mining industry of Chifeng in Inner Mongolia. Mr. Li and Mr. Mu have worked together as partners for over 20 years. They are both considered role models for the local industry. From 1978 to 1998, Mr. Mu served as the Manager of Finance for the Weng Niu Te County Dong Zi Cave Lead-Zinc Company. From 1999 to 2010, he served as the General Manager of Weng Niu Te County Huanggutun Mining. From 2011 to present, he serves as the Chairman of Weng Niu Te County Long Xiang Kuang Ye Mining Company. Mr. Mu is a major stock holder of IGC.

Advisor: Mr. Wen Sang has been an attorney for the past 10 years. He currently practices law at the Germany City Law Firm in China. Mr. Wen’s experience includes several public listings on the Hong Kong stock exchange and extensive work on Mergers and Acquisitions in China including in the mining sector. He has done due diligence on Iron ore mines in the Inner Mongolia region and has an expertise in both corporate and mining regulations in China. He graduated in 2006 from Wuhan University with a Master in Law.

About IGC:
Based in Bethesda, Maryland, India Globalization Capital (IGC) is a materials and infrastructure company operating in India and China. We currently supply Iron ore to Steel Companies operating in China and rock aggregate to the infrastructure industry in India. For more information about IGC, please visit IGC’s Web site at www.indiaglobalcap.com.

Forward-looking Statements:
Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential,” “proposed,” or “continue” or the negative of those terms. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of IGC concerning PRC Ironman with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our competitive environment, infrastructure demands, Iron ore availability and governmental, political, economic, legal and social conditions in China.

Factors that could cause actual results to differ, relate to the (i) ability of IGC to successfully execute on contracts and business plans, (ii) ability to raise capital and the structure of such capital including the exercise of warrants, (iii) exchange rate changes between the U.S. dollar, the Chinese RMB and the Indian rupee, (iv) weather conditions in China and India, (v) uncertainties with respect to the People’s Republic of China’s legal and regulatory environment, and (vi) ability of the Company to access ports on the coasts of India. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC’s amended Annual Report on Form 10-K for the year ended March 31, 2011 and Schedule 14A filed on December 9, 2011 with the Securities and Exchange Commission.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact Information
Investor Relations Contact:
Mr. John Selvaraj

THQ (THQI) and Zuffa Announce Transition of UFC Videogame Rights

THQ Inc. (NASDAQ: THQI) and Zuffa, LLC, today announced that they have reached an agreement resulting in Zuffa licensing to Electronic Arts Inc. (NASDAQ: EA) the right to publish videogames based on the Ultimate Fighting Championship^® (UFC^®) brand, effective today. The agreement results in an undisclosed cash payment to THQ. Additionally, THQ will continue to publish its existing console and mobile titles through March 31, 2013.

“Over the last three years, THQ has delivered best-in-class, all-encompassing experiences to MMA fans, sports enthusiasts and fighting gamers around the globe with its UFC Undisputed^™ series. We want to thank them for their stewardship of our brand,” said Dana White, President, UFC. “We look forward to joining forces with EA to leverage their sports platform, and expand our brand in the video game space.”

Brian Farrell, THQ’s Chairman and CEO, commented, “We have relished our relationship with UFC over the last several years and believe that the UFC gaming brand is in great shape. THQ’s more focused strategy moving forward meant that transferring the license to EA made sense to all parties. We would like to thank UFC for their great support and partnership and wish EA all the best moving forward.”

About Ultimate Fighting Championship®

Owned and operated by Zuffa, LLC, and headquartered in Las Vegas, Nev., UFC® is the world’s premier MMA organization and produces over 12 UFC live Pay-Per-View events annually around the globe. In 2012, FOX will broadcast four fights annually. In spring 2012, The Ultimate Fighter®, UFC’s signature weekly reality TV show, debuts on FX. UFC content is also distributed commercially to bars and restaurants through Joe Hand Promotions in the U.S. Globally, UFC programming is broadcast in over 149 countries and territories, reaching a half a billion homes worldwide, in 20 different languages.

UFC® also boasts a powerful presence online, with UFC.com attracting over seven million unique visitors per month, while also possessing one of the most powerful social media followings in all of professional sports. To date, UFC has over six million fans on Facebook and over 400,000 followers on Twitter. In addition, UFC President Dana White is one of the most accessible and most followed executives in sports with more than 1.7 million followers on Twitter. On January 22, 2011, UFC continued to set trends in social media, becoming the first major sports league to stream live, broadcast quality action on Facebook.

Ancillary businesses include best-selling DVDs, a magazine, the best-selling UFC “Undisputed” videogame franchise distributed by THQ, UFC GYM®, UFC Fight Club affinity program, UFC Fan Expo® festivals, branded apparel, trading cards, and articulated action figures.

About THQ

THQ Inc. (NASDAQ: THQI) is a leading worldwide developer and publisher of interactive entertainment software. The company develops its products for all popular game systems, personal computers, wireless devices and the Internet. Headquartered in Los Angeles County, California, THQ sells product through its global network of offices located throughout North America, Europe and Asia Pacific. More information about THQ and its products may be found at http://www.thq.com/. THQ and its logo are trademarks and/or registered trademarks of THQ Inc.

THQ Inc. Caution Concerning Forward-Looking Statements

This press release contains statements that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the business of THQ Inc. and its subsidiaries (collectively referred to as “THQ”), including, but not limited to, expectations with respect to the transfer of the UFC license from THQ to Electronic Arts. These statements are based upon management’s current beliefs and certain assumptions made by management. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, business, competitive, economic, legal, political, and technological factors affecting our industry, operations, markets, products, or pricing. Readers should carefully review the risk factors and the information that could materially affect THQ’s financial results, described in other documents that THQ files from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal period ended March 31, 2011 and subsequent Quarterly Reports on Form 10-Q, and particularly the discussion of trends and risk factors set forth therein. Unless otherwise required by law, THQ disclaims any obligation to update its view on any such risks or uncertainties or to revise or publicly release the results of any revision to these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Multiband (MBND) Announces Stock Buy Back Plan

Cascade Microtech (CSCD) Industry’s First Fully-Automatic High-Power Device Measurement Probe

BEAVERTON, OR — (Marketwire) — 06/04/12 — Cascade Microtech, Inc. (NASDAQ: CSCD), a leading expert at enabling precision measurements of integrated circuits at the wafer level, today introduced the new APS200TESLA. This innovative, turn-key system combines the proven capabilities of its Tesla on-wafer power device characterization measurement technology with Cascade Microtech’s BlueRay™ production automation technology to deliver the industry’s first complete on-wafer production solution to address the test challenges of discrete power devices.

As power semiconductors grow with the demand for energy-efficient and environmentally-friendly products, power device manufacturing will shift from silicon substrates to silicon carbide (SiC), gallium nitride (GaN), and gallium nitride on silicon (GaN-on-Si). These new substrate technologies offer improved efficiency and enable higher levels of power, and faster switching, in many applications using insulated gate bipolar transistors (IGBTs) and MOSFETS, such as automotive and consumer electronics, electrical power distribution and large data centers.

Fast-growing applications in renewable energy and industrial power will challenge power device manufacturers to develop more efficient devices at a lower cost, driving the need for test solutions specifically designed for high-voltage/high-current probing. Cascade Microtech meets this challenge with the first fully-automatic on-wafer probe system for high-power device measurement. Rated up to 10k V/400 A, the APS200TESLA delivers unmatched electrical performance for high-voltage and high-current device characterization at production levels. The system comes with a high-voltage/high-current probe card, a high-voltage/high-power chuck port, and the patent-pending MicroVac™ high-power chuck that can handle wafer thicknesses down to 50 µm, such as the ultra-thin Taiko wafers. An optimized electrical connection easily integrates the APS200TESLA with a variety of test instruments, and the interlock-enabled safety shield provides a safe environment for the operator. The arc-suppression feature allows the customer to optimize device layout to achieve better yields. Auto-discharging and the unique probe-pin touch sensing capability prevent device damage due to high-voltage discharge during die-to-die moves. The APS200TESLA also offers advanced prober control software for automatic wafer and die stepping.

“The new APS200TESLA leverages our experience in achieving accurate on-wafer measurement. It is an advanced, turn-key power device measurement system that will help our customers improve cost-of-ownership, increasing test throughput and improving yields,” said Michael Burger, president and CEO, Cascade Microtech, Inc. “It allows our customers to save time by avoiding unnecessary dicing and packaging prior to final test. By testing on-wafer in a production environment, the APS200TESLA enables our customers to reduce test costs and get their products to market faster.”

About Cascade Microtech, Inc.
Cascade Microtech, Inc. (NASDAQ: CSCD) is a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures. For technology businesses and scientific institutions that need to evaluate small structures, Cascade Microtech delivers access to electrical data from wafers, ICs, IC packages, circuit boards and modules, MEMS, 3D TSV, LED devices and more. Cascade Microtech’s leading-edge stations, probes, probe cards and integrated systems deliver precision accuracy and superior performance both in the lab and during production manufacturing of high-speed and high-density semiconductor chips. For more information visit www.cascademicrotech.com.

FOR MORE INFORMATION, CONTACT:

Laurie A. Winton
Cascade Microtech, Inc.
(503) 601-1934

Opnext (OPXT) Determines Unsolicited Offer to Acquire Company Is Not Superior

Opnext, Inc. (NASDAQ:OPXT), a global leader in the design and manufacture of optical modules and components, today announced that on May 31, 2012, the board of directors of Opnext determined that an unsolicited non-binding offer to acquire all of the issued and outstanding capital stock of Opnext for $1.40 per share was not superior to Opnext’s proposed merger with Oclaro, Inc. The offer had been received on May 23, 2012 from a technology-focused private equity firm with significant available capital and was subject to the performance of due diligence by the private equity firm. After careful consideration and consultation with its financial and legal advisors and with Opnext management, Opnext’s board of directors determined that the offer was not financially more favorable to Opnext’s stockholders than the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of March 26, 2012, entered into among Opnext, Oclaro, Inc., and Tahoe Acquisition Sub, Inc.

Opnext notes that significant progress has been made on the pending merger with Oclaro and that Opnext believes, subject to receipt of the required stockholder approvals of Opnext and Oclaro and other remaining third party regulatory consents, the merger is on target for a closing early in the third calendar quarter of 2012.

Additional Information and Where to Find It

This communication is being made in respect of the proposed business combination involving Opnext and Oclaro. In connection with the proposed transaction, Opnext and Oclaro have filed and plan to file documents with the Securities and Exchange Commission, including the filing by Oclaro on May 8, 2012 of a Registration Statement on Form S-4 containing a Joint Proxy Statement/Prospectus, and each of Opnext and Oclaro plan to file other documents with the SEC regarding the proposed transaction. Investors and security holders of Opnext and Oclaro are urged to carefully read the Joint Proxy Statement/Prospectus (when available) and other documents filed with the SEC by Opnext and Oclaro as they will contain important information about the proposed transaction. Investors and security holders may obtain free copies of the documents filed with the SEC on Opnext’s website at www.opnext.com or Oclaro’s website at www.oclaro.com or the SEC’s website at www.sec.gov. Opnext, Oclaro and their respective directors and executive officers may be deemed participants in the solicitation of proxies with respect to the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction will be included in the Joint Proxy Statement/Prospectus described above. Additional information regarding the directors and executive officers of Opnext is also included in Opnext’s proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on January 26, 2012.

Cautionary Statement Regarding Forward-Looking Statements

Certain of the statements in this release are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that are not limited to historical facts, but reflect Opnext’s and Oclaro’s current beliefs, expectations or intentions regarding future events. Words such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Opnext’s and Oclaro’s expectations with respect to the anticipated financial benefits of the proposed transaction; approval of the proposed transaction by stockholders; the satisfaction of the closing conditions to the proposed transaction; and the timing of the completion of the proposed transaction. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of Opnext and Oclaro and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) the failure of the merger to close for any reason; (ii) the competitive position and opportunities for the combined company; (iii) general business and economic conditions; (iv) the performance of financial markets; (v) risks relating to the consummation of the contemplated merger, including the risk that required stockholder approval and regulatory agencies might not be obtained in a timely manner or at all or that other closing conditions are not satisfied; (vi) the impact on the merger on the markets for the combined companies optical, industrial and consumer products; (vii) the failure of the combined company to realize synergies and cost-savings from the transaction or delay in realization thereof; (viii) the businesses or employees of Opnext and Oclaro not being combined and integrated successfully, or such combination taking longer or being more difficult, time-consuming or costly to accomplish than expected; (ix) operating costs and business disruption following the merger, including adverse effects on employee retention and on our business relationships with third parties; (x) the future performance of the combined company following the closing of the merger; (xi) the combined company’s ability to maintain gross margins; (xii) effects of fluctuating product mix on results; (xiii) the combined company’s ability to timely develop and commercialize new products; (xiv) the combined company’s ability to respond to evolving technologies and customer requirements; (xv) the combined company’s dependence on a limited number of customers for a significant percentage of its projected revenues; (xvi) the combined company’s ability to effectively compete with companies that have greater name recognition, broader customer relationships and substantially greater financial, technical and marketing resources; (xvii) increased costs related to downsizing and compliance with regulatory requirements in connection with such downsizing, competition and pricing pressure; (xviii) the combined company’s potential lack of availability of credit or opportunity for equity based financing; (xix) the combined company’s risks associated with international operations; (xx) the combined company’s outcome of tax audits or similar proceedings; and (xxi) the outcome of litigation pending against Opnext or Oclaro. Additional factors that can cause the results to materially differ than those described in the forward-looking statements can be found in the most recent Form 10-Q, most recent Form 10-K and other periodic reports filed by Opnext and Oclaro, with the Securities and Exchange Commission. They each anticipate subsequent events and developments may cause their views and expectations to change. Neither Opnext nor Oclaro assumes any obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

(OPXT-G)

About Opnext:

Opnext (NASDAQ:OPXT) is the optical technology partner of choice supplying systems providers and OEMs worldwide with one of the industry’s largest portfolio of 10Gbps and higher next generation optical products and solutions. The Company’s industry expertise, future-focused thinking and commitment to research and development combine in bringing to market the most advanced technology to the communications, defense, security and biomedical industries. Formed out of Hitachi, Opnext has built on more than 30 years of experience in advanced technology to establish its broad portfolio of solutions and solid reputation for excellence in service and delivering value to its customers. For additional information, visit www.opnext.com.

BioSante (BPAX) to Present at Jefferies Global Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M. Simes, BioSante’s president & CEO will present a corporate update at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 11:00 am EDT.

Mr. Simes will provide an overview of BioSante, as well as an update on the LibiGel^® (testosterone gel) Phase III clinical development program, and a review of published results using BioSante’s GVAX Cancer Immunotherapies in combination with ipilimumab (Ipi; Yervoy; BMS).

A live audio webcast of remarks by Mr. Simes may be accessed at http://wsw.com/webcast/jeff68/bpax/. The webcast will be archived for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante´s products include LibiGel^® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSante´s other products include a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc., and for which a New Drug Application (NDA) was approved by the FDA in February 2012, and the Pill-Plus™, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante´s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, is marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee. Additional information is available online at: www.biosantepharma.com.

Vimicro (VIMC) Chairman and CEO Meers with Chinese Minister of Public Security

BEIJING, June 1, 2012 /PRNewswire-Asia-FirstCall/ — Vimicro International Corporation (NASDAQ: VIMC) (“Vimicro” or the “Company”), a leading multimedia semiconductor and IP-based surveillance solution provider, today announced that Vimicro’s Chairman and CEO, Dr. John Deng, met with China’s State Councilor and Minister of Public Security, Mr. Jianzhu Meng, on May 24, 2012 in Beijing. The meeting took place before Dr. Deng delivered a speech on the Internet of Things and Public Security to a national audience of police officers, both onsite and via video conference. During the meeting, Mr. Meng highly praised the role that SVAC (Surveillance Video and Audio Coding) plays in strengthening China’s law enforcement and also thanked Dr. Deng and the other scientists and engineers who participated in the development of this national standard.

Earlier this year, the Chinese Ministry of Public Security issued a “Task Mandate for All Public Security Agencies Regarding Video Image Integration and Sharing,” and has officially adopted Vimicro’s SVAC standard as a core required industry standard in China. Previously, the SVAC standard was approved and officially released by the Standardization Administration of China in December 2010.

“We are pleased that SVAC has been selected as a core required technology standard by the Ministry of Public Security,” commented Dr. John Deng, Vimicro’s Chairman  and CEO. “We firmly believe that SVAC will significantly advance the domestic surveillance market and that the use of SVAC-based chips and related products will become commonplace in China. We look forward to SVAC chips and products also becoming a significant growth driver for Vimicro as we further develop the technology.”

About SVAC

The Surveillance Video and Audio Coding (SVAC) is the first national standard for the Chinese security and surveillance industry and is considered crucial for the establishment of the public security and criminal prevention system in China. SVAC has been approved and officially released by the Standardization Administration of China and the first Research Institute of the Ministry of Public Security of China. SVAC was initiated and co-developed by Vimicro and the Ministry of Public Security, along with contributions from more than 40 scientific research institutes, universities and security industry companies. SVAC aims to promote the orderly development of the surveillance industry in China, while enabling greater interconnectivity and providing more intelligent data analysis through the use of digital technologies and rules-based processes. SVAC is also the first fundamental technology that will enable surveillance’s transition from the analog world to a fully digital, high definition, open and intelligent surveillance network.  SVAC is the preferred protocol in Chinese government contracts and available to all companies participating in the surveillance industry in China.

About Vimicro International Corporation

Vimicro International Corporation is a leading multimedia semiconductor and solution provider that designs, develops and markets mixed-signal semiconductor products and system-level solutions that enable multimedia capabilities in a variety of products for PC/Notebook, consumer electronics and surveillance markets. Vimicro is aggressively expanding business into the surveillance market with system-level solutions and semiconductor products to capitalize on China’s domestic demand. Vimicro’s ADSs, each of which represents four ordinary shares, are currently trading on the NASDAQ Global Market under the ticker symbol “VIMC.”

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the quotations from management in this announcement, as well as Vimicro’s expectations and forecasts, contain forward-looking statements. Vimicro may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission on forms 20-F and 6-K, etc., in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Vimicro’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the company’s ability to develop and sell new mobile multimedia products; the expected growth of the mobile multimedia market; the company’s ability to increase sales of notebook camera multimedia processors; the company’s ability to retain existing customers and acquire new customers and respond to competitive market conditions; the company’s ability to respond in a timely manner to the evolving multimedia market and changing consumer preferences and industry standards and to stay abreast of technological changes; the company’s ability to secure sufficient foundry capacity in a timely manner; the company’s ability to effectively protect its intellectual property and the risk that it may infringe on the intellectual property of others; and cyclicality of the semiconductor industry. Further information regarding these and other risks is included in Vimicro’s annual report on Form 20-F filed with the Securities and Exchange Commission. Vimicro does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of the date hereof, and Vimicro undertakes no duty to update such information, except as required under applicable law.

Tanzanian Royalty (TRX) Finds More High-Grade Gold Zones

Tanzanian Royalty Exploration Corporation is pleased to announce that it has received further assays from its ongoing deep drilling program at the Buckreef Gold Project in Tanzania. This hole is part of a program of drilling designed to extend and confirm the mineralisation potential at depth.

Key points:

• Highlight is 12 metres grading 5.22g/t gold from 336 metres in drill hole BMDD158 which include 5 metres grading 7.31g/t gold from 341 metres. This is the best result from deep drilling sampling at Buckreef.
• The intersected gold zone is characterized by brecciated quartz vein and strong silica-sericite-carbonate-pyrite alteration.
• The deep drilling program has provided the first opportunity to sample the deep mineralisation at Buckreef and confirmed the width and grade of gold mineralization at depth.

The intersection reported here is a core length and may not represent true width but the true width is estimated to be 50 – 60%.

The gold mineralization at the Buckreef is hosted in shear zones emplaced along the fine grained basaltic sequence, medium grained dolerite and strongly altered felsic porphyry units, associated with gold-bearing quartz-sericite-carbonate-pyrite alteration assemblages. The best gold grades are confined within brecciated and altered dolerite with felsic porphyry intercalation and grey quartz vein with fine disseminated pyrite.

“We are pleased with this higher grade assay results from core drilling at Buckreef,” commented Joseph K. Kahama, Chairman and Chief Operating Officer (Tanzania). “These results show that our drilling has been successful and has provided the first opportunity to sample the deep mineralisation at Buckreef.” He further added, “This drill intercept has confirmed the width and gold grade of greater than 12m wide hydrothermal veined mineralized system with a well developed silica-sericite-carbonate-pyrite alteration. This will serve to further increase our level of confidence associated with the Buckreef Gold Project and, we expect, increase our resource base meanwhile, all mineralized zones below a vertical depth of 350m below surface remain largely untested.”

Sample Protocol and QA/QC

The samples chain of custody is managed by Buckreef technical team under the supervision of Anthony Minde. Core samples are picked up from the drill site at the end of every shift by Company personnel for direct delivery to the secured drill core storage house locate next to the Buckreef exploration office. The storage is accessible only by approved personnel.

Intervals of core to be analyzed are split with a mechanized core cutter in half with one half to be sent to the laboratory for geochemical analysis and the remaining half to be kept in the storage for future reference and uses. Sample to be assayed will remain under the control of Company personnel until submitted to SGS laboratory in Mwanza for 50g fire assay (FA) with AAS finish (0.01ppm LLD). The average percentage of recovery core is 95%. Sample intervals of 1m or less but greater than 0.5m depended on geology.

SGS laboratory is ISO 90001 and 17025 accredited and employs a Laboratory Information Management System for sample tracking, quality control and reporting. In addition to SGS internal standards materials and blank samples, the Company regularly inserts into every batch its own certified standards, coarse blanks and duplicate sample in the sample stream approximately every 20 samples.

Qualified Person

The Company’s Qualified Persons, Mr. Phillip Kaniki and Charles Mnguto, have reviewed and approved the content of this news release. Mr. Phillip Kaniki has a Bachelor of Science in Geology degree from the University of Dar es Salaam (1997) and is a registered scientist with MAusIMM (Reg. No 221963). Mr. Charles Mnguto has a Bachelor of Science in Geology (Hons) degree from the University of Dar es Salaam (1995) and is registered scientist with MAusIMM (Reg. No 307793).

Respectfully Submitted,

Joseph Kahama

Chairman and Chief Operating Officer (Tanzania)

For further information, please contact Investor Relations at 1-800-811-3855

Visit our website: www.TanzanianRoyalty.com

The Toronto Stock Exchange and NYSE Amex Equities have not reviewed and do not accept responsibility for the adequacy or accuracy of this release

Cautionary Note to U.S. Investors – The United States Securities and Exchange Commission limits disclosure for U.S. reporting purposes to mineral deposits that a company can economically and legally extract or produce. We use certain terms on this news release, such as “reserves”, “resources”, “geologic resources”, “proven”, “probable”, “measured”, “indicated”, or “inferred” which may not be consistent with the reserve definitions established by the SEC. U.S. Investors are urged to consider closely the disclosure in our SEC filings. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml

This news release contains certain forward-looking statements and forward-looking information. All statements, other than statements of historical fact, included herein are forward-looking statements and forward-looking information that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time-to-time with the British Columbia, Alberta and Ontario provincial securities regulatory authorities.

Certain information presented in this release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on numerous assumptions, and involve known and unknown risks, uncertainties and other factors, including risks inherent in mineral exploration and development, which may cause the actual results, performance, or achievements of the Company to be materially different from any projected future results, performance, or achievements expressed or implied by such forward-looking

statements. Investors are referred to our description of the risk factors affecting the Company, as contained in our SEC filings, including our annual report on Form 20-F and Registration Statement on Form F-10, as amended, for more information concerning these risks, uncertainties, and other factors.

Majesco (COOL) to Present at the Needham 7th Annual Internet & Digital Media Conference

EDISON, NJ — (Marketwire) — 06/01/12 — Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of video games for the mass market, announced today that Mike Vesey, Chief Financial Officer, will be presenting at the Needham 7th Annual Internet and Digital Media Conference being held in New York City.

Mr. Vesey is scheduled to present on Tuesday, June 5 at 1:00 p.m. Eastern Time.

A live audio webcast may be accessed through the investor relations portion of Majesco Entertainment’s Web site, located at ir.majescoentertainment.com. The webcast and presentation will also be archived on the Web site for 90 days following the presentation.

About Majesco Entertainment Company
Majesco Entertainment Company is a provider of video games for the mass market. Building on more than 20 years of operating history, the company is focused on developing and publishing a wide range of casual and family oriented video games on all leading console and handheld platforms as well as online, social networks and mobile devices. Product highlights include Zumba® Fitness, Cooking Mama™, and Alvin and the Chipmunks. The company’s shares are traded on the NASDAQ Stock Market under the symbol: COOL. Majesco is headquartered in Edison, NJ with offices in San Francisco, CA, Brockhampton, UK, and a social games development studio in Foxboro, MA. More info can be found online at www.majescoentertainment.com or on Twitter at www.twitter.com/majesco.

Safe Harbor

During the course of the presentation, Majesco may make forward-looking statements regarding future events or the future financial performance of the company. Statements including words such as “anticipate,” “believe,” “estimate” or “expect” and statements in the future tense are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from the expectations set forth in the forward-looking statements. Some of the factors which could cause our results to differ materially from our expectations include the following: consumer demand for our products, the consumer demand for videogame consoles and related hardware; our ability to predict consumer preferences among competing hardware platforms; consumer spending trends; the seasonal and cyclical nature of the interactive game segment; timely development and release of our products; competition in the interactive entertainment industry; developments in the law regarding protection of our products; our ability to secure licenses to valuable entertainment properties on favorable terms; our ability to manage expenses; our ability to attract and retain key personnel; adoption of new accounting regulations and standards; adverse changes in the securities markets; our ability to comply with continued listing requirements of the Nasdaq stock exchange; the availability of and costs associated with sources of liquidity; and other factors described in our filings with the SEC. The Company does not undertake, and specifically disclaims any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

For additional information, please contact:

Todd Greenwald
CFA
Director of Investor Relations & Strategic Planning
732-476-1938

Supertel Hospitality (SPPR) Announces Sale of Kansas Super 8 for $4.1M

NORFOLK, NE — (Marketwire) — 06/01/12 — Supertel Hospitality, Inc. (NASDAQ: SPPR), a real estate investment trust (REIT), today announced that it closed on the sale of a Super 8 hotel in Wichita, Kansas on June 1, 2012, at a sale price of $4.1 million. Developed by Supertel in February 1989, the 119-room hotel was purchased by the City of Wichita to facilitate a highway expansion project. Supertel used the proceeds from the sale to fully retire the $3.1 million mortgage on the property, and the balance went to reduce the company’s short term borrowings.

About Supertel Hospitality, Inc.

Supertel Hospitality, Inc. (NASDAQ: SPPR) is a self-administered real estate investment trust that specializes in the ownership of select-service hotels. The company currently owns 96 hotels comprising 8,467 rooms in 23 states. Supertel’s hotels are franchised by a number of the industry’s most well-regarded brand families, including Hilton, IHG, Choice and Wyndham. For more information or to make a hotel reservation, visit www.supertelinc.com.

Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statement. These risks are discussed in the company’s filings with the Securities and Exchange Commission.

Contact:
Ms. Krista Arkfeld
Director of Corporate Communications
karkfeld@supertelinc.com

Rodman & Renshaw (MKTS) Announces Name and Ticker Change

Direct Markets Holdings Corp. and “MKTS” Effective June 1, 2012

Rodman & Renshaw Capital Group, Inc. (Formerly NASDAQ: RODM) announced that it changed its name to Direct Markets Holdings Corp. (NASDAQ: MKTS) effective today, June 1, 2012, and its common stock began trading today under the ticker MKTS. Rodman & Renshaw, LLC, our broker-dealer subsidiary, continues to operate under the name of Rodman & Renshaw, LLC.

About Direct Markets Holdings Corp.

Direct Markets Holdings Corp. (NASDAQ: MKTS) is a holding company with a number of direct and indirect subsidiaries, including Direct Markets, Inc. and Rodman & Renshaw, LLC.

About Direct Markets, Inc.

Direct Markets, Inc. will operate an automated state-of-the-art electronic transaction platform to directly link existing public company issuers and investors seeking to transact primary offerings of securities. The DirectMarkets platform will bring unprecedented, cost-efficient access to the capital markets into the C-Suite of public companies and bypass certain traditional roles typically held by investment banks that presently control the transactional process. Both investors and issuers will benefit from 24/7 seamless access to the DirectMarkets platform through a graphical user interface (GUI) accessible via a desktop or laptop computer, as well as mobile smart devices such as tablets or smartphones. For more information, please visit www.directmkts.com.

About Rodman & Renshaw, LLC

Rodman & Renshaw, LLC is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. The company also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent by deal volume of PIPE and RD financing transactions completed every year since 2005. For more information, please visit www.rodm.com.

MEMBER FINRA, SIPC

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements regarding future events and financial performance including, but not limited to the timing and success of the roll-out of the DirectMarkets platform. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements.

These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K, filed March 16, 2012, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

PharmAthene (PIP) Awarded 50% of Net Profits Over 10 Years in Court Ruling

Delaware Chancery Court Issues Final Order And Judgment Upholding Its Favorable Ruling – Court Provides Clarity on Payment Process to PharmAthene

The Bon-Ton Stores, Inc. (BONT) Announces May Sales

~Comparable Store Sales Increased 1.5% ~

The Bon-Ton Stores, Inc. (NASDAQ: BONT) today announced comparable store sales in the four weeks ended May 26, 2012 increased 1.5%. Total sales increased 1.2% to $183.1 million in the current year compared with $181.0 million in the prior year period.

Year-to-date comparable store sales decreased 0.7%. Year-to-date total sales decreased 0.8% to $823.9 million compared with $830.9 million in the same period last year.

Brendan Hoffman, President and Chief Executive Officer, commented, “We are pleased with our May sales performance, as compelling new offerings and refinements in our marketing efforts yielded positive results. Our eCommerce business continued to post double-digit sales increases, and we are very encouraged that our aggressive pursuit of traditional product resulted in an improved performance in ladies’ ready-to-wear, particularly moderate sportswear, as customers responded favorably to new receipts. Month-end comparable store inventories increased approximately 3% over the prior year, reflecting increased investment to support our sales initiatives. We look to drive sustained improved performance as we continue to implement our merchandising and marketing strategies.”

Keith Plowman, Executive Vice President and Chief Financial Officer, stated, “Our excess borrowing capacity under our revolving credit facility was approximately $423 million at the end of May.”

The Bon-Ton Stores, Inc., with corporate headquarters in York, Pennsylvania and Milwaukee, Wisconsin, operates 272 department stores, which includes 11 furniture galleries, in 23 states in the Northeast, Midwest and upper Great Plains under the Bon-Ton, Bergner’s, Boston Store, Carson Pirie Scott, Elder-Beerman, Herberger’s and Younkers nameplates and, in the Detroit, Michigan area, under the Parisian nameplate. The department stores offer a broad assortment of national and private brand fashion apparel and accessories for women, men and children, as well as cosmetics and home furnishings. For further information, please visit the investor relations section of the Company’s website at http://investors.bonton.com.

Certain information included in this press release contains statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which may be identified by words such as “may,” “could,” “will,” “plan,” “expect,” “anticipate,” “estimate,” “project,” “intend” or other similar expressions, involve important risks and uncertainties that could significantly affect results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. Factors that could cause such differences include, but are not limited to, risks related to retail businesses generally; a significant and prolonged deterioration of general economic conditions which could negatively impact the Company, including the potential write-down of the current valuation of intangible assets and deferred taxes; changes in the terms of the Company’s proprietary credit card program; potential increase in pension obligations; consumer spending patterns, debt levels, and the availability and cost of consumer credit; additional competition from existing and new competitors; inflation; deflation; changes in the costs of fuel and other energy and transportation costs; weather conditions that could negatively impact sales; uncertainties associated with expanding or remodeling existing stores; the ability to attract and retain qualified management; the dependence upon relationships with vendors and their factors; a data security breach or system failure; the ability to reduce or control SG&A expenses, including initiatives to reduce expenses and improve efficiency; operational disruptions; unsuccessful marketing initiatives; the failure to successfully implement our key strategies, including initiatives to improve our merchandising, marketing and operations; adverse outcomes in litigation; the incurrence of unplanned capital expenditures; the ability to obtain financing for working capital, capital expenditures and general corporate purpose; the impact of new regulatory requirements including the Credit Card Accountability Responsibility and Disclosure Act of 2009 and the Health Care Reform Act; the inability or limitations on the Company’s ability to favorably adjust the valuation allowance on deferred tax assets; and the financial condition of mall operators. Additional factors that could cause the Company’s actual results to differ from those contained in these forward-looking statements are discussed in greater detail under Item 1A of the Company’s Form 10-K filed with the Securities and Exchange Commission.

ImmunoCellular (IMUC) to Present Long-term Oncology Survival Data

ImmunoCellular Therapeutics to Present Long-term Survival Data from Clinical Study of ICT-107 in Glioblastoma Multiforme at American Society of Clinical Oncology Meeting

ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company’s lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. The abstract, titled “Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine” (Abstract #2087), has been accepted for presentation on June 2, 2012 from 1:15 PM to 5:15 PM, during the Central Nervous System Tumors General Poster Session. The data will show that there is downregulation of both the tumor associated antigens that ICT-107 is targeting as well as CD-133, a cancer stem cell (CSC) marker, in some of the patients. These observations suggest that targeting antigens highly expressed by CSCs is a promising strategy for treating patients with GBM.

Updated data from the 16 patients in the Phase I trial shows that patients treated with ICT-107 reported overall survival (OS) of 50% after four years and 38% of the trial patients are progression free (PFS) for 48-66 months. This compares very favorably to historic mean OS of 12.1% after four years and 5.6 % PFS after 48 months with standard of care alone.

While not all 16 of the patients in the Phase I trial have crossed the five-year time point, three of the patients are disease-free for five years. Cancer stem cell population measured by CD-133 in patients who went through a second surgery has gone down by a multiple of 3-5 times. Usually the CSC population goes up 3-5 times with the standard of care treatment alone, which appears to validate ICT-107’s mechanism of action. The positive trend between the expression of gp-100, MAGE-1, AIM-2 and Her-2 and PFS appears to indicate that those cells are more susceptible to respond to the vaccination. In addition, several of these antigens were downregulated over time, further validating the mechanism of action of ICT-107. This new data follows previously announced two-year results showing an OS rate of 80% and a PFS rate of 44%, which compare very favorably to historic median survival rates with standard of care alone.

In ImmunoCellular’s follow-on Phase II trial of ICT-107, there are 213 patients enrolled to date, of which 100 patients have been either randomized (or treated with the product) or are waiting to complete radiation therapy prior to treatment. The Company recently announced that its Phase II trial is now on-going at 25 sites, with patients enrolled in leading medical centers such as Mass General Cancer Center and the Dana Farber Cancer Institute. ImmunoCellular plans to continue enrollment for a short time to ensure enough patients will be available for the data analysis. The trial, as originally designed, was to enroll over 200 patients to treat at least 102 patients with HLA-A1/A2 immunological subtypes.

“The continued impressive survival data we have seen to date and the timely enrollment in our ongoing Phase II trial, further build our confidence that targeting CSCs may provide a breakthrough in the treatment of GBM,” said Manish Singh, Ph.D., President and CEO of ImmunoCellular. “As we complete enrollment of our Phase II trial, we look forward to obtaining patient data.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials in statistically significant larger patient populations; and the risks associated with adhering to clinical timeframes. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Penson (PNSN) and PEAK6 Announce Formation of Apex Clearing

Prima BioMed (PBMD) to Host Shareholder Briefing

SYDNEY, AUSTRALIA — (Marketwire) — 05/31/12 — Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) advises that it will hold a shareholder briefing with the Company’s CEO designate Matthew Lehman, current CEO Martin Rogers, Chairman Lucy Turnbull, and Deputy Chairman Albert Wong in Sydney, Australia, on Friday, 15 June 2012.

The briefing will provide an opportunity for Mr. Lehman to meet shareholders and deliver an update on the Company’s activities.

Mr. Lehman, who is currently Prima’s Chief Operating Officer, will become the Company’s CEO effective 1 September 2012 (see ASX announcement of 24 May).

Details of the shareholder briefing:

Date:
Friday, 15 June 2012

Time:
9:30am to 11:00am AEST (local time)

Venue:
Radisson Blu Hotel Sydney
27 O’Connell St Sydney (Marble Room 2 and 3)

Shareholders outside Sydney will be able to access the briefing via a webcast and dial-in facility. Webcast and dial-in details will be provided on the Prima BioMed and ASX websites prior to the meeting.

Shareholders, and other interested parties, are kindly requested to RSVP to enquiries@primabiomed.com.au prior to the event to assist in planning the meeting. Shareholders are also encouraged to submit questions or comments via email prior to the meeting.

Prima has updated the Company Calendar section of its website to include this shareholder briefing and other relevant upcoming public presentations.

About Prima BioMed

Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalised bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximise value to shareholders. Prima’s lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.

For further information please contact:

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52

MicroVision (MVIS) Receives Purchase Orders in Excess of $4M

MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it has received purchase orders from Pioneer Corporation valued in excess of $4 million. The purchase orders cover key components, including MEMS and electronics, which are part of the company’s patented next generation HD PicoP^® display technology based on direct green lasers (PicoP Gen2) that Pioneer is integrating into its Cyber Navi car navigation system.

Pioneer is MicroVision’s first customer under its Image by PicoP ingredient brand business model whereby it sells components and receives license fees and royalties for its patented PicoP display technology. Pioneer’s Cyber Navi head-up display (HUD) is the first commercial product based on MicroVision’s PicoP Gen2 display technology.

MicroVision has already begun shipping components to Pioneer for its aftermarket HUD product that is expected to be available in Japan in July. The Cyber Navi is the world’s first HUD to project augmented reality information in front of the windscreen and the world’s first onboard HUD to use lasers. The product was designed to offer drivers a new way to experiencing data on the road.

Pioneer will combine the MEMS and electronics it receives from MicroVision with red, blue and direct green lasers from Pioneer’s laser suppliers to create optical engines based on MicroVision’s patented PicoP reference design. The PicoP display technology embedded in the HUD delivers bright, clear, full color images viewable in daylight in a small form factor with low power requirements.

About MicroVision

MicroVision provides the PicoP® display technology platform designed to enable next-generation display and imaging products for consumer devices, vehicle displays and wearable displays. The company’s PicoP projection display technology uses highly efficient laser light sources which can create vivid images with high contrast and brightness.

MicroVision is an independently recognized leader in the development of intellectual property. MicroVision has been recognized by IEEE as a top 20 IP portfolio among all global electronics companies, and the top U.S. Company in the rankings. MicroVision’s intellectual property portfolio has also been recognized by the Patent Board, in association with the Wall Street Journal as a top 50 IP portfolio among all global industrial companies. The Patent Board has developed more than 50 indicators that track global patent activity relating to companies’ innovation, technology, and science strengths. MicroVision’s intellectual property portfolio is further recognized by having been added to the Ocean Tomo 300 Patent Index. The Index is priced and published by the NYSE Euronext (NYSE: OTPAT). The index is objectively based on the value of intellectual property compared to competitors.

For more information, visit us on:

Forward-Looking Statements

Certain statements contained in this release, including those relating to future products and operating results, and those using words such as “designed to” and “will” and words with similar meanings are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the forward-looking statements include the following: our ability to raise additional capital when needed; our or our customers’ failure to perform under purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

Synthesis (SYMX) Initiates Pre-Commissioning on Syngas Plant Startup at Yima Joint Venture

HOUSTON, May 30, 2012 /PRNewswire/ — Synthesis Energy Systems, Inc. (Nasdaq: SYMX) (“SES”) announced today that it has deployed a pre-commissioning team to the Yima Joint Venture project in Henan Province, China. This team will inspect the SES technology, equipment and related gasification systems at the Yima Joint Venture project over the next several weeks to ensure the installation is ready to operate as designed once construction is completed. The first syngas production from the project is expected this summer.

The pre-commissioning team is comprised of SES China technology and engineering team members as well as several operations and maintenance personnel from the Company’s Zao Zhuang Joint Venture project in Zao Zhuang City, Shandong Province, China. Once the pre-commissioning and construction periods are complete, the project will advance into the commissioning phase during which the team will complete operating systems functionality tests ahead of the project startup.

Colin Tam, Managing Director of SES China, stated, “The successful startup of the Yima Joint Venture Project is an important milestone for our company not only in China but also globally. We have recently mobilized our pre-commissioning team to assist our partner Yima in their planned startup this summer.  We look forward to working diligently with our partner to complete the project on schedule and within budget.”

Robert Rigdon, SES President and CEO, commented, “I am pleased that our project is advancing well. We believe this large scale chemicals facility will provide the Yima Joint Venture with meaningful revenues and earnings once in full commercial operation, and that SES’ 25% ownership share in the Yima Joint Venture will enable us to grow more rapidly in China. This large-scale project is very important to SES as many of our customers in China and globally desire to move rapidly to implement our technology at large scale to benefit from our very low cost coal capability.”

About Synthesis Energy Systems, Inc.

SES provides technology, equipment and engineering services for the conversion of low rank, low cost coal and biomass feedstocks into energy and chemical products. Its strategy is to create value through providing technology and equipment in regions where low rank coals and biomass feedstocks can be profitably converted into high value products through its proprietary U-GAS® fluidized bed gasification technology, which SES licenses from the Gas Technology Institute. U-GAS® gasifies coal cost effectively, without many of the harmful emissions normally associated with coal combustion plants. The primary advantages of U-GAS® relative to other gasification technologies are (a) greater fuel flexibility provided by the ability of SES to use all ranks of coal (including low rank, high ash and high moisture coals, which are significantly cheaper than higher grade coals), many coal waste products and biomass feed stocks; and (b) the ability of SES to operate efficiently on a smaller scale, which enables the construction of plants more quickly, at a lower capital cost, and, in many cases, in closer proximity to coal sources. SES currently has offices in Houston, Texas, and Shanghai, China. For more information on SES and SRS, visit www.synthesisenergy.com or call (713) 579-0600.

SES Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the early stage of development of SES, its estimate of the sufficiency of existing capital sources, its ability to successfully develop its licensing business, its ability to raise additional capital to fund cash requirements for future investments and operations including its China platform initiative, its ability to reduce operating costs, the limited history and viability of its technology, commodity prices and the availability and terms of financing opportunities, its results of operations in foreign countries, its ability to diversify, its ability to complete the restructuring of the ZZ Joint Venture, its ability to obtain the necessary approvals and permits for its future projects, the estimated timetables for achieving mechanical completion and commencing commercial operations for the Yima project as well as the ability of the Yima project to produce revenues and earnings, the sufficiency of internal controls and procedures and the ability of SES to effect the ZJX/China Energy transaction, grow its business and generate revenues and earnings as a result of its proposed China and India platform initiatives, as well as its joint venture with Midas Resource Partners. Although SES believes that in making such forward-looking statements its expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Important Notice from SES

In connection with the proposed ZJX/China Energy transaction, SES has filed a preliminary proxy statement, and intends to file a definitive proxy statement, with the SEC and intends to mail the definitive proxy statement to the stockholders of SES. SES and its directors and officers may be deemed to be participants in the solicitation of proxies from the stockholders of SES in connection with the transaction. Information about the transaction is set forth in the preliminary proxy statement filed, and will be set forth in the definitive proxy statement to be filed by SES with the SEC.

You may obtain the preliminary statement and, when available, the definitive proxy statement, for free by visiting EDGAR on the SEC website at www.sec.gov. Investors should read the definitive proxy statement carefully before making any voting or investment decision because that document will contain important information.

Zogenix (ZGNX) Submits IND for Second DosePro(R) Candidate Relday(TM)

Potential First Needle-Free Subcutaneous Treatment Option in $2 Billion Long-Acting Injectable Antipsychotic Market

SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) — Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration (FDA) for Relday™, which is a combination of Zogenix’s DosePro^® needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. In July 2011, Zogenix licensed from DURECT (Nasdaq:DRRX) exclusive global rights to develop and commercialize this proprietary formulation which utilizes DURECT’s SABER^® depot technology. Initial clinical trials are currently planned to begin in the second half of the year, with results expected by year-end.

Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately $2 billion in 2011, with currently approved products using a 21-gauge or larger needle for intramuscular injections. The leading product in the category requires twice-a-month dosing and drug reconstitution prior to use. The combined market for oral and injectable antipsychotic products was estimated at more than $16 billion in 2010.

If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing. Zogenix believes that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to DURECT’s SABER controlled-release formulation technology in combination with Zogenix’s DosePro needle-free subcutaneous drug delivery system.

Roger L. Hawley, chief executive officer of Zogenix, said, “We are encouraged by Relday’s potential of improving patient compliance due to the safety and convenience provided by DosePro’s needle-free delivery system combined with a long-acting formulation of an established antipsychotic. Our market research indicates that psychiatrists prefer a subcutaneous, needle-free, once-monthly treatment option over products that are currently available.”

Hawley continued, “We anticipate having study results toward the end of the year which could position us to begin discussions regarding a rest-of-world development and commercialization partner. Should Relday receive FDA approval, it will also further validate the potential use of DosePro to enable the delivery of viscous drug formulations such as biologics.”

About DosePro^®

The DosePro system is a first-in-class, easy-to-use drug delivery system that includes a pre-filled, single dose of liquid drug, and is administered subcutaneously, without a needle. The platform is currently used by Zogenix’s first commercial product, SUMAVEL^® DosePro^®, and its investigational candidate, Relday. The Company believes that DosePro offers several benefits to patients compared to other subcutaneous delivery methods, and that it has the potential to become a preferred delivery option for patients and physicians. These benefits include less anxiety or fear due to the lack of a needle, easier disposal without the need for a sharps container, no risk of needle stick injury or contamination, an easy-to-use three step process, no need to fill or manipulate the device, reliable performance, discreet use and portability. In several clinical trials and market research studies, DosePro has been shown to be preferred by patients over conventional needle-based systems.

Zogenix has entered into an agreement with Battelle, an independent research and development organization, to co-market the DosePro technology to potential pharmaceutical and government clients with the objective of licensing the system for use with innovative therapeutics that would be enabled or enhanced by DosePro’s unique needle-free delivery system. Compared to other delivery technologies, DosePro has the potential to solve the significant challenges of delivering viscous drug formulations, such as high concentration biologics, which cannot be delivered with traditional needle-based injection. The DosePro drug delivery technology is covered by more than 46 internationally issued patents extending through 2026.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix’s first commercial product, SUMAVEL^® DosePro^® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead investigational product candidate, Zohydro™ (hydrocodone bitartrate) is a novel, oral, single-entity (without acetaminophen) extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix submitted an NDA to the FDA for Zohydro in May 2012. Zogenix’s second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

For additional information, please visit www.zogenix.com.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming” and similar expressions are intended to identify forward-looking statements. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding development of a commercially successful product, the initiation of clinical trials and results from such trials and the timing thereof, the ability of such product to address the global anti-psychotic market, the ability to develop a once-monthly injectable product with improved pharmacokinetics and significant reduction in injection volume, ability to achieve first-in-class status, partnering opportunities for Relday outside the United States, and leveraging the DosePro technology. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix’s business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as Relday, including the timing and outcome of the FDA’s review of the IND for Relday; difficulties in identifying, negotiating, executing and carrying out strategic transactions relating to Relday; the market potential for anti-psychotics, and Zogenix’s ability to compete within that market; ability to obtain and the validity and duration of patent protection and other intellectual property rights for Relday; and other risks described in the company’s prior press releases and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM are trademarks of Zogenix, Inc.

SABER^® is a trademark of DURECT Corporation.

CONTACT: Investor Contact
         Zack Kubow| The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         Media Contact
         The Ruth Group
         Victoria Aguiar
         646.536.7013 | vaguiar@theruthgroup.com

Thomas Properties Group, Inc. (TPGI) Private Placement of $50M in Common Stock

Thomas Properties Group, Inc. (NASDAQ:TPGI) announced today that it has entered into a definitive purchase agreement with certain institutional accredited investors affiliated with Madison International Realty with respect to the private placement of 8,695,693 shares of its common stock at a purchase price of $5.75, per share, for expected gross proceeds of approximately $50 million before payment of estimated transaction expenses. The closing of this private placement is expected to occur on or about June 12, 2012, subject to customary closing conditions. On May 29, 2012, the closing price of the company’s common stock on the NASDAQ Global Market was $4.05 per share.

In connection with the purchase agreement, the investors also entered into a Stockholders’ Agreement with TPGI and James A. Thomas, our Chairman and Chief Executive Officer, and certain stockholders affiliated with Mr. Thomas, providing for certain lock-up, standstill, preemptive rights and voting agreements by TPGI, the investors, Mr. Thomas and the other affiliated stockholders. The investors will have the right to name one person to become a director of TPGI at the next regular meeting of the Board of Directors. In addition, TPGI entered into a registration rights agreement with the investors pursuant to which it has granted certain rights for the filing of registration statements under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the registration for resale of the shares of common stock issued in the private placement, certain other shares of common stock currently owned by the investors and securities acquired pursuant to the exercise of preemptive rights.

No underwriting discounts or commissions will be paid by TPGI with respect to the sale of the shares, but TPGI has agreed to reimburse the investors for certain transaction expenses. Net proceeds of the private placement will be used for general corporate purposes, including potential acquisitions.

This private placement of securities was made only to select institutional accredited investors in accordance with Section 4(2) under the Securities Act and the rules and regulations promulgated thereunder. The securities offered in this private placement have not been registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold in the United States or to any U.S. persons absent registration with the Securities and Exchange Commission (the “SEC”) and any applicable state securities laws, or an applicable exemption therefrom.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Madison International Realty

Madison International Realty (www.madisonint.com) is a leading liquidity provider to real estate investors and companies worldwide. Madison provides strategic equity capital for recapitalizations, partner buyouts and balance sheet restructurings through the acquisition of joint venture, limited partner and co-investment interests as principals and invests in equity securities of undervalued public companies. With approximately $1 billion in assets under management, Madison invests in direct secondary transactions and directly in companies focused on Class A properties and portfolios in the U.S., U.K., and Western Europe. Founded in 1996, Madison has offices in New York, London and Frankfurt, Germany.

About Thomas Properties Group

Thomas Properties Group, Inc., based in Los Angeles, is a full-service real estate company that owns, acquires, develops and manages primarily office, as well as mixed-use and residential properties on a nationwide basis. The company’s primary areas of focus are the acquisition and ownership of premier properties, both on a consolidated basis and through its strategic joint ventures, property development and redevelopment, and property management and leasing activities. For more information about Thomas Properties Group, Inc., please visit www.tpgre.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, statements made in this press release, including those relating to the private placement and the use of proceeds therefrom, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the company’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. For a discussion of some of the factors that may cause our results to differ from management’s expectations, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Factors That May Influence Future Results of Operations” in our Form 10-K for the year ended December 31, 2011, and our Quarterly Reports on Form 10-Q and other filings with the SEC. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NCI (NCIT) Awarded National Institute of Health’s CIO-SP3 GWAC with $20B Ceiling

NCI, Inc. (NASDAQ:NCIT), a leading provider of information technology (IT) and professional services and solutions to U.S. Federal Government agencies, announced today that it was an awardee on the $20B ceiling Chief Information Officers-Solutions and Partners (CIO-SP3) Government Wide Acquisition Contract (GWAC). The National Institutes of Health (NIH) Information Technology Acquisition and Assessment Center (NITAAC) posted the awards. The broad-based IT contract focuses on health and biomedical-related IT services, with a period of performance is 10 years, and representing new business for NCI.

Under the contract, NCI is eligible to compete for task orders in ten functional areas including Healthcare IT Services, Chief Information Officer (CIO) Support, Imaging, Outsourcing, IT Operations and Maintenance, Integration Services, Government Outsourcing, Critical Infrastructure Protection and Information Assurance, Digital Government, Enterprise Management Systems, and Software Development. CIO-SP3 is a successor to the highly successful CIO-SP2i and the Image World2 New Dimensions GWACs.

“NCI is delighted to have been awarded the CIO-SP3 contract. This award enables NCI and its large and small business teammates to provide a wide array of innovative solutions in health IT and other functional areas to NIH and other federal agencies. The award further expands our portfolio of major prime GWAC, IDIQ and other multiple-award vehicles, particularly in the area of federal health IT,” said NCI’s President, Brian Clark.

About NCI, Inc.:

NCI is a leading provider of IT and professional services and solutions to U.S. Federal Government agencies. NCI’s award-winning expertise encompasses areas critical to its customers’ mission objectives, including enterprise systems management; network engineering; cybersecurity and information assurance; software development and systems engineering; program management, acquisition, and lifecycle support; engineering and logistics; health IT and informatics; and training and simulation. The company is a member of the Russell 2000 and S&P Small Cap 600 indexes. Headquartered in Reston, VA, NCI has approximately 2,300 employees at more than 100 locations worldwide. For more information, visit our website at www.nciinc.com, or email mcrystal@nciinc.com.

Forward-Looking Statement: Statements and assumptions made in this press release, which do not address historical facts, constitute “forward-looking” statements that NCI, Inc. believes to be within the definition in the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties, many of which are outside of our control. Such forward-looking statements are subject to factors that could cause actual results to differ materially from those anticipated results. These factors include but are not limited to: the failure of the Government to allot funds to NCI to complete performance of the contract; the risk of contract performance; government contract procurement (such as bid protest) and termination risks; competitive factors such as pricing pressures and/or competition to hire and retain employees; and material changes in laws or regulations applicable to the company’s businesses. For a discussion of these and other risks and uncertainties, please refer to the section titled “Risk Factors” in the NCI, Inc. Form 10-K filed with the Securities and Exchange Commission for the period ended December 31, 2011. The forward-looking statements included in this news release are only made as of the date of this news release and NCI, Inc. undertakes no obligation to publicly update any of the forward-looking statements made herein, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Trovagene, Inc. (TROV) 1.15M Units, NASDAQ Listing, Effectiveness of Reverse Stock Split

SAN DIEGO, May 30, 2012 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV),a developer of trans-renal molecular diagnostics, announced the pricing of an underwritten public offering of 1,150,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will begin trading on The NASDAQ Capital Market on May 30, 2012 under the symbol “TROVU.” The common stock and warrants will not be separately transferable until the earlier of (i) the exercise in full of the underwriters’ overallotment option or (ii) 45 days from the date of the prospectus. Each warrant will have an exercise price of $5.32 per share, will be exercisable upon separation of the units and will expire five years from the closing of the offering. When separately transferable, the warrants will trade on The NASDAQ Capital Market under the symbol “TROVW.” The gross proceeds to Trovagene from this offering are expected to be $9.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 4, 2012, subject to customary closing conditions. Trovagene has also granted the underwriters a 45-day option to purchase up to an additional 172,500 units to cover over-allotments, if any. All of the units in the offering are to be sold by Trovagene.

Trovagene intends to use the net proceeds from this offering to fund its research and development activities, and for working capital and other general corporate purposes and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

Trovagene also announced that, effective as of May 30, 2012, its common stock will begin trading on The NASDAQ Capital Market under the symbol “TROV.”  In connection with its listing on The NASDAQ Capital Market, Trovagene’s common stock will cease trading on the OTC QB.  Furthermore, in connection with this offering, Trovagene has effected a 1-for-6 reverse stock split of its common stock which is effective for trading purposes as of May 30, 2012.

Aegis Capital Corp. is acting as the sole book-running manager.

Summer Street Research Partners and Brean Murray, Carret & Co., LLC are acting as co-managers.  A registration statement on Form S-1 relating to the units was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 11th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Company:
Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

GlobalWise (GWIV) to Hold Inaugural Partner Advisory Board Meeting

COLUMBUS, OH — (Marketwire) — 05/30/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announces an inaugural Partner Advisory Board meeting is taking place in Columbus, Ohio, from May 29 – May 31.

The Partner Advisory Meeting was established by GlobalWise CEO William J. “BJ” Santiago in order to bring together the various forms of sales distribution into a single location to share best practices for selling ECM software services, as well as to jointly develop future applications and improvements to the software portfolio. With ECM software applications being needed for every industry, and any size business, the concern for channel conflict or sharing of trade secrets between competitors is minimal and actually encouraged for the benefit of all those involved.

“I am excited to be hosting the inaugural Partner Advisory Meeting,” stated William J. “BJ” Santiago, CEO of GlobalWise. “Many of our key, strategic Channel Resellers are in attendance for a fantastic event that will be held over a three day period. I see this as an excellent educational forum for our selling partners to get together and learn how each other uses and actively sells our software portfolio. Equally important, our software developers are hearing directly from sales channel partners what the market is asking for so that we are always on the cutting-edge of technology, similar to our migration from premise-based software to an Internet cloud based service delivery model.”

Participants at the inaugural meeting include various Channel Partners who actively market ECM solutions directly to business clients. Those Channel Partners include FormFast, ImageSoft, Primary Solutions, MWA Intelligence (MWAi) and many others. These partners cover a wide range of industries throughout the United States, including state and county governments, insurance, healthcare, court systems and educational institutions. With MWAi, the Company has the opportunity to expand beyond North America into the Asian and EMEA markets internationally.

Also attending is Lexmark International, Inc., which has integrated the Intellivue™ ECM software into their multi-function copiers and printers service offering. Lexmark developed the private-labeled DocMP (Document Management Platform) service that delivers Lexmark clients a multi-function copier and printer embedded with the ECM document management functions provided by Intellinetics’ Intellivue™ software. To see how Lexmark has integrated the Intellivue™ ECM technology into the DocMP platform, please click the following link to watch a YouTube video demonstration: http://youtu.be/69mnWMFy7uA.

“Lexmark is a marquee relationship for GlobalWise and Intellinetics,” added Santiago. “By integrating the Intellivue™ software into an industry-leading hardware manufacturer like Lexmark, we instantly expanded our sales opportunities with a low-cost, private-labeled sales distribution model. Similar to our Channel Distribution model, this hardware integration approach is another method to expand our sales scope for our software products with cost-effective customer acquisition strategies. I think all of our sales distribution partners will enjoy the three day event and will leave with exciting new ways to market ECM solutions.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

CytRx (CYTR) Details INNO-206 Clinical Cancer Research Publication Findings

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma. The research was published in the May 22, 2012 online issue of peer-reviewed Clinical Cancer Research.

“Anthracyclines including doxorubicin have shown efficacy especially in combination with other therapies for the treatment of multiple myeloma; however, side effects limit their use,” said James R. Berenson, M.D., Medical & Scientific Director at the Institute for Myeloma & Bone Center Research, where the studies were conducted. “We found that, in our mouse models of human myelomas, INNO-206 alone produced marked anti-multiple myeloma effects at a dose at which doxorubicin alone was extremely toxic, and the combination of INNO-206 and bortezomib produced increased anti-multiple myeloma effects compared to either agent alone.”

Dr. Berenson presented earlier research showing that INNO-206 safely and effectively delivered doxorubicin at higher doses than conventional doxorubicin to human myeloma cancers grown in immune-deficient mice. These findings were presented at the December 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH).

CytRx President and CEO Steven A. Kriegsman said, “This study provides further evidence that INNO-206 could have applicability in multiple cancer indications. We are initially conducting clinical trials with INNO-206 in soft tissue sarcoma and more recently in advanced pancreatic ductual adenocarcinomas.”

Complete results from the CytRx Phase 1b/2 clinical trial with INNO-206 in patients principally with soft tissue sarcoma will be presented at the June American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois, on Sunday, June 3. CytRx will host an investor conference call accompanied by a slide presentation on Monday, June 4, at 9:00 a.m. Central time (10:00 a.m. Eastern time) to discuss the complete clinical trial data. To access the conference call, dial 888-463-4383 (U.S. and Canada) or 706-679-5355 (international callers).

The webcast and the slide presentation will be available on the Investor Relations section of the CytRx website simultaneously. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 77958605.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and recently initiated a Phase 2 trial for patients with advanced pancreatic ductual adenocarcinomas. CytRx’s pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and which is in a clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the timing, outcome or results of any future pre-clinical or clinical testing of INNO-206 as a treatment for multiple myeloma, the risk that any future human testing of INNO-206 for multiple myeloma might not produce results similar to those seen in animals, risks or uncertainties related to the outcome, timing and results of CytRx’s clinical trials with INNO-206, including the Phase 1b/2 clinical trial for INNO-206 in patients with advanced solid tumors and the Phase 2b clinical trials for INNO-206 as a treatment for soft tissue sarcomas and pancreatic cancer, uncertainties regarding regulatory approvals for current and future clinical testing, and the scope of the clinical testing that may eventually be required by regulatory authorities, the risk that INNO-206 might not show greater efficacy than doxorubicin notwithstanding the administration of higher doses than the standard of care, uncertainties regarding whether INNO-206 effectively targets doxorubicin to tumors, the significant time and expense that will be incurred in developing any of the potential commercial applications for INNO-206, including for soft tissue sarcomas, risks related to CytRx’s ability to manufacture its drug candidates, including INNO-206, in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including any future clinical development of INNO-206, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

China Automotive Systems (CAAS) Redeems All Convertible Notes